Enveric Biosciences Inc (ENVB)

$4.15 +0.39 (10.37%)
Market Cap 2.28M
Revenue (ttm) 0.00
Net Income (ttm) -9.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 100,175
Avg Vol 882,498
Day's Range N/A - N/A
Shares Out 597,000.00
Stochastic %K 33%
Beta 0.30
Analysts Strong Buy
Price Target $10.00

Company Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules...

Industry: Biotechnology
Sector: Healthcare
Address:
245 First Street, Riverview II 18 th Floor, Cambridge, United States
Tony_37
Tony_37 Jan. 14 at 8:48 PM
$ENVB : 86 k volume.. wait until over millions 🚀🤔
0 · Reply
Tony_37
Tony_37 Jan. 14 at 8:46 PM
$ENVB : after hour run ??
0 · Reply
Tony_37
Tony_37 Jan. 14 at 4:59 PM
$ENVB : 1 m float .. can squeeze anytime 🚀🤔🎁
0 · Reply
Luckyjs38
Luckyjs38 Jan. 14 at 4:50 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 14 at 4:34 PM
$ENVB Loading up for the break out into price discovery 🐦‍🔥
0 · Reply
RBLUCKY
RBLUCKY Jan. 14 at 3:29 PM
$ENVB looks like they need to get some more patents they helped the stock a lot!
0 · Reply
zeph1985
zeph1985 Jan. 14 at 10:31 AM
$ENVB dcx moveable
0 · Reply
Tony_37
Tony_37 Jan. 13 at 11:00 PM
$ENVB : earning expect 3/30 .. just add more anh wait .. 🤔🎁
0 · Reply
Tony_37
Tony_37 Jan. 13 at 4:32 PM
$ENVB : all time low $3.50
0 · Reply
Iucky7
Iucky7 Jan. 13 at 8:02 AM
$ENVB Short Shares Availability: 30,000 Fee: 64.91
0 · Reply
Latest News on ENVB
Enveric Biosciences Announces Patent Issuance

Dec 29, 2025, 8:00 AM EST - 16 days ago

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 12, 2025, 4:46 PM EST - 4 weeks ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 11, 2025, 1:43 PM EST - 4 weeks ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Dec 9, 2025, 8:00 AM EST - 5 weeks ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Dec 4, 2025, 8:00 AM EST - 5 weeks ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Nov 26, 2025, 8:00 AM EST - 7 weeks ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Nov 14, 2025, 4:05 PM EST - 2 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Enveric Biosciences Announces Reverse Stock Split

Oct 23, 2025, 8:00 AM EDT - 2 months ago

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 16, 2025, 8:30 AM EDT - 3 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 15, 2025, 8:00 AM EDT - 3 months ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 14, 2025, 9:00 AM EDT - 3 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Oct 2, 2025, 8:45 AM EDT - 3 months ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 18, 2025, 4:30 PM EDT - 4 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 4 months ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 17, 2025, 8:00 AM EDT - 4 months ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 16, 2025, 8:45 AM EDT - 4 months ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 4 months ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Sep 2, 2025, 8:30 AM EDT - 4 months ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 28, 2025, 8:30 AM EDT - 4 months ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Aug 14, 2025, 8:00 AM EDT - 5 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 23, 2025, 8:03 AM EDT - 6 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jul 15, 2025, 9:03 AM EDT - 6 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 24, 2025, 9:03 AM EDT - 7 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 16, 2025, 10:46 AM EDT - 7 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 10, 2025, 9:03 AM EDT - 7 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Jun 3, 2025, 9:00 AM EDT - 8 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025, 9:03 AM EDT - 8 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025, 8:00 AM EDT - 8 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025, 4:15 PM EDT - 8 months ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 31, 2025, 8:00 AM EDT - 10 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 17, 2025, 1:40 PM EDT - 10 months ago

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Mar 6, 2025, 10:00 AM EST - 11 months ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 27, 2025, 9:30 AM EST - 11 months ago

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 25, 2025, 1:30 PM EST - 11 months ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 4, 2025, 8:00 AM EST - 1 year ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Announces Closing of $5 Million Public Offering

Feb 3, 2025, 5:00 PM EST - 1 year ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Jan 30, 2025, 8:14 PM EST - 1 year ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Jan 30, 2025, 4:01 PM EST - 1 year ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Jan 6, 2025, 8:30 AM EST - 1 year ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Dec 2, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Nov 25, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Nov 14, 2024, 4:05 PM EST - 1 year ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Nov 12, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Announces Broad Range of Patent Issuances

Nov 4, 2024, 10:36 AM EST - 1 year ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Aug 12, 2024, 5:30 PM EDT - 1 year ago

Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results

Tony_37
Tony_37 Jan. 14 at 8:48 PM
$ENVB : 86 k volume.. wait until over millions 🚀🤔
0 · Reply
Tony_37
Tony_37 Jan. 14 at 8:46 PM
$ENVB : after hour run ??
0 · Reply
Tony_37
Tony_37 Jan. 14 at 4:59 PM
$ENVB : 1 m float .. can squeeze anytime 🚀🤔🎁
0 · Reply
Luckyjs38
Luckyjs38 Jan. 14 at 4:50 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 14 at 4:34 PM
$ENVB Loading up for the break out into price discovery 🐦‍🔥
0 · Reply
RBLUCKY
RBLUCKY Jan. 14 at 3:29 PM
$ENVB looks like they need to get some more patents they helped the stock a lot!
0 · Reply
zeph1985
zeph1985 Jan. 14 at 10:31 AM
$ENVB dcx moveable
0 · Reply
Tony_37
Tony_37 Jan. 13 at 11:00 PM
$ENVB : earning expect 3/30 .. just add more anh wait .. 🤔🎁
0 · Reply
Tony_37
Tony_37 Jan. 13 at 4:32 PM
$ENVB : all time low $3.50
0 · Reply
Iucky7
Iucky7 Jan. 13 at 8:02 AM
$ENVB Short Shares Availability: 30,000 Fee: 64.91
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Jan. 13 at 3:54 AM
$BBGI $ENVB $OSRH $LVLU You are destined to be RICH 🤑
0 · Reply
Luckyjs38
Luckyjs38 Jan. 12 at 10:58 PM
$ENVB i hope we see a settlement offer with $ABBV ? when paperwork to be submitted for stage 1 trails EB-003 ❤️
0 · Reply
JustTradingHoy
JustTradingHoy Jan. 12 at 5:14 PM
$ENVB almost full the gap on the December pop. Shorts probably look to cover in low to mid $3
0 · Reply
GTMStox
GTMStox Jan. 12 at 3:25 PM
$ENVB $MBRX These Biotech scams never cease to amaze me.
0 · Reply
Tony_37
Tony_37 Jan. 12 at 2:48 PM
$ENVB : day to cover increases.. take more time .. waiting game here 💎🎁
0 · Reply
Tony_37
Tony_37 Jan. 12 at 1:49 AM
$ENVB : 8k filled
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Jan. 12 at 1:28 AM
Small-Cap with Catalysts this week: 👇👇 ( $AUUD, $XRTX, $OFAL, $LGVN, $ENVB, etc...) #NASDAQ #NYSE
0 · Reply
Tony_37
Tony_37 Jan. 11 at 2:22 PM
$ENVB hope good news can pump this ticker 💎🎁
0 · Reply
ChartChartist
ChartChartist Jan. 10 at 11:44 PM
$SCNI sitting $MTEX lets go sexy $SNSE climbing channel $ENVB idk okay tho $HWH lets gooo. #1 ticker hwh , get on it
0 · Reply
Tony_37
Tony_37 Jan. 10 at 1:07 PM
$ENVB : Monday 💎
0 · Reply
JohnTrack
JohnTrack Jan. 10 at 6:17 AM
$ENVB new presentation https://www.rapidticker.com/news/envb-sec-filing-fe8bf9
1 · Reply
Luckyjs38
Luckyjs38 Jan. 9 at 7:08 PM
$ENVB Break free you track star
0 · Reply